PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes. "The new medicines we are looking at are called SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors.

Heart disease is the single biggest killer of men and women in New Zealand, and the Heart Foundation is calling for people to show their big heart by volunteering as a street collector for its Big Heart Appeal on Friday 21 and Saturday 22 February.

Breast Cancer Aotearoa Coalition (BCAC) is delighted to hear that Ibrance (palbociclib) will be funded by PHARMAC from 1 April 2020.

More than half of aged care residents are not eating enough and are missing out on essential vitamins and other nutrients despite being offered a variety of food, Otago research shows.

PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer.

Pharmac’s announcement this morning that it aims to fund Ibrance (palbociclib) for Kiwis with advanced breast cancer (ABC) from April 2020 is wonderful news for patients and for all who have campaigned for the drug over the past few years.

A nationwide campaign to raise awareness for the 300,000 New Zealanders living with a rare disorder is to be launched at the Grand Hall in Parliament on Friday 28 February.

A University of Otago researcher has made an innovative discovery which paves the way for advances in treating cardiovascular disease including high blood pressure.

The study, led by Auckland University of Technology (AUT) Emeritus Professor of Nutrition, Elaine Rush, measured carotenoids (orange-coloured pigments) in the skin as a biomarker of vegetable and fruit intake.

Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment.